These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24306948)

  • 21. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Our inability to predict thromboembolic events after prosthetic valve surgery.
    Will MB; Bernacca GM; Bell EF; Tolland MM; Lowe GD; Rumley A; Murray HM; Ford I; Wheatley DJ
    J Heart Valve Dis; 2006 Jul; 15(4):570-80; discussion 580. PubMed ID: 16901057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
    Flierl U; Fraccarollo D; Micka J; Bauersachs J; Schäfer A
    Pharmacol Res; 2013 Aug; 74():49-55. PubMed ID: 23714416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aniticoagulation in patients following prosthetic heart valve replacement.
    Akhtar RP; Abid AR; Zafar H; Khan JS
    Ann Thorac Cardiovasc Surg; 2009 Feb; 15(1):10-7. PubMed ID: 19262444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivaroxaban in patients with mechanical heart valves: A pilot study.
    Roost E; Weber A; Alberio L; Englberger L; Reineke D; Keller D; Nagler M; Carrel T
    Thromb Res; 2020 Feb; 186():1-6. PubMed ID: 31837559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With a Mechanical Prosthesis.
    Durães AR; Bitar YSL; Lima MLG; Santos CC; Schonhofen IS; Filho JAL; Roever L
    Am J Cardiol; 2018 Sep; 122(6):1047-1050. PubMed ID: 30098707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
    De Backer O; Dangas GD; Jilaihawi H; Leipsic JA; Terkelsen CJ; Makkar R; Kini AS; Veien KT; Abdel-Wahab M; Kim WK; Balan P; Van Mieghem N; Mathiassen ON; Jeger RV; Arnold M; Mehran R; Guimarães AHC; Nørgaard BL; Kofoed KF; Blanke P; Windecker S; Søndergaard L;
    N Engl J Med; 2020 Jan; 382(2):130-139. PubMed ID: 31733182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
    Oswald E; Velik-Salchner C; Innerhofer P; Tauber H; Auckenthaler T; Ulmer H; Streif W
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):136-44. PubMed ID: 25396759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful use of fondaparinux for bridging early after aortic and mitral mechanical heart valve replacement.
    Perissinotti AJ; Dotson B; Baciewicz FA; Tennenberg SD
    Ann Pharmacother; 2012 Mar; 46(3):e9. PubMed ID: 22353236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry.
    Hammerstingl C; Tripp C; Schmidt H; von der Recke G; Omran H
    J Heart Valve Dis; 2007 May; 16(3):285-92. PubMed ID: 17578050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A practical approach for bridging anticoagulation after mechanical heart valve replacement.
    Steger V; Bail DH; Graf D; Walker T; Rittig K; Ziemer G
    J Heart Valve Dis; 2008 May; 17(3):335-42. PubMed ID: 18592932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
    Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats.
    Demirtas A; Azboy I; Bulut M; Ucar BY; Alabalik U; Necmioglu NS
    Eur Rev Med Pharmacol Sci; 2013 Jul; 17(14):1850-6. PubMed ID: 23877846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rivaroxaban (Xarelto): efficacy and safety].
    Rosencher N; Arnaout L; Chabbouh T; Bellamy L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty years' single-center experience with mechanical heart valves: a critical review of anticoagulation policy.
    Van Nooten GJ; Caes F; François K; Van Bellleghem Y; Bové T; Vandenplas G; Taeymans Y
    J Heart Valve Dis; 2012 Jan; 21(1):88-98. PubMed ID: 22474748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
    Komotar RJ; Starke RM; Connolly ES
    Neurosurgery; 2008 Oct; 63(4):N10-1. PubMed ID: 18981864
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.